A phase 2 trial investigating the efficacy and safety of the mPGES-1 inhibitor vipoglanstat in systemic sclerosis-related Raynaud's
一项二期临床试验正在研究mPGES-1抑制剂vipoglanstat治疗系统性硬化症相关雷诺氏症的疗效和安全性。
期刊:Rheumatology
影响因子:4.4
doi:10.1093/rheumatology/keae049
Tornling, Göran; Edenius, Charlotte; Pauling, John D; Denton, Christopher P; Olsson, Anna; Kowalski, Jan; Murray, Andrea; Anderson, Marina; Bhat, Smita; Del Galdo, Francesco; Hall, Frances; Korkosz, Mariusz; Krasowska, Dorota; Olas, Jacek; Smith, Vanessa; van Laar, Jacob M; Vonk, Madelon C; Wojteczek, Anna; Herrick, Ariane L